SANTHERA PHARMACEUTICALS HOLDING AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.77 CHF | -2.01% |
|
-8.46% | -10.60% |
| 19/06 | Transcript : Santhera Pharmaceuticals Holding AG - Special Call | |
| 18/06 | Santhera Secures CHF69 Million Financing for Bond Repayment, Cash Runway Extension | MT |
Presentation Operator MessageOperator (Operator)Ladies and gentlemen, welcome to the new finan...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Santhera Pharmaceuticals Holding AG (Santhera) is a Switzerland-based company engaged in the pharmaceutical sector. The Company operates through one business segment, which is the research, development and commercialization of pharmaceutical products for the treatment of neuromuscular and mitochondrial diseases, such as Duchenne muscular dystrophy (DMD) and cystic fibrosis (CF). The Company focuses also on development of gene therapy for the treatment of LAMA2 (Laminin Subunit Alpha 2) deficient congenital muscular dystrophy (CMD). Santhera operates through its wholly owned subsidiaries: Santhera Pharmaceuticals (Schweiz) AG, Liestal, Santhera Pharmaceuticals (USA) Inc, Santhera Pharmaceuticals (Canada) Inc, Santhera Pharmaceutical (Deutschland) GmbH and Oy Santhera Pharmaceuticals (Finland) Ltd.
Sector
Pharmaceuticals
Calendar
04/09/2024
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
8.95
CHF
Average target price
34.5
CHF
Spread / Average Target
+285.47%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -10.60% | 91.91M | |
| +7.95% | 72.21B | |
| +14.98% | 9.14B | |
| -24.60% | 4.33B | |
| +15.26% | 4.28B | |
| +28.46% | 4.15B | |
| +7.76% | 2.19B | |
| -35.98% | 1.98B | |
| +7.76% | 1.98B | |
| -47.71% | 1.68B |
- Stock Market
- Equities
- SANN Stock
- News Santhera Pharmaceuticals Holding AG
- Transcript : Santhera Pharmaceuticals Holding AG - Special Call
